Form 8-K - Current report:
SEC Accession No. 0001213900-22-084094
Filing Date
2022-12-30
Accepted
2022-12-30 17:00:14
Documents
13
Period of Report
2022-12-30
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea171085-8k_actinium.htm   iXBRL 8-K 35928
2 FOURTH AMENDMENT TO THE ACTINIUM PHARMACEUTICALS, INC. 2019 PLAN ea171085ex10-1_actinium.htm EX-10.1 7111
  Complete submission text file 0001213900-22-084094.txt   220801

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE atnm-20221230.xsd EX-101.SCH 3245
4 XBRL LABEL FILE atnm-20221230_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE atnm-20221230_pre.xml EX-101.PRE 22371
7 EXTRACTED XBRL INSTANCE DOCUMENT ea171085-8k_actinium_htm.xml XML 3612
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 221502477
SIC: 2834 Pharmaceutical Preparations